All Issues
In silico identification of a potent arsenic based lead drug di-phenyl phenoxy roxarsone against SARS-CoV-2
Author : Trinath Chowdhury a, Joyita Dutta b, Santi M. Mandal a and Gourisankar Roymahapatra *b
DOWNLOAD PDF
ABSTRACT
In this article we have tried to address the plausible identification of a novel lead drug molecule against COVID-19. Nine different arsenic (As) based molecules, roxarsone derivatives were designed and optimized for computational analysis to determine its binding affinity against SARS-CoV-2. The molecules were screened based on their chemical reactivity with respect to conceptual density functional theory (CDFT) and global reactivity descriptors. The screened molecules were docked blindly against RNA dependent RNA polymerase (RdRp) using molecular docking software iGEMDOCK v2.1. On the basis of idock score in their respective catalytic domain, di-phenyl phenoxy roxarsone identified as promising inhibitor against SARS-CoV-2 with binding free energy calculated as –86.8 kcal/mol. Site specific docking was also executed with target site, receptor binding domain (RDB) of spike glycoprotein of SARS-CoV-2 whose structure was computationally designed using Phyre2 server. The interaction study of RDB with di-phenyl phenoxy roxarsone revealed a binding energy –133.3 kcal/mol. Thus it can be concluded from the above in silico experiment that screening of potential arsenic based roxarsone derivative would help in development of new therapeutic drug for COVID-19.
KEYWORD
Drug molecule design, di-phenyl phenoxy roxarsone, COVID-19, in silico experiment